Keep an eye on TG Therapeutics (TGTX).
Just yesterday, the US FDA approved the company’s multiple sclerosis drug for adults with a relapsing form of the disease. One source, says TipRanks.com, suggested TGTX could see at least $1 billion in sales from it within two years.
Unfortunately, TGTX doesn’t reflect that potential, says JPMorgan. In fact, analyst Eric Joseph – who has an overweight rating on the stock, with a $21 price target – says he continues to see current TGTX price levels as “under-reflecting” the MS drug. H.C. Wainwright analysts also raised their price target on TGTX to $24 from $19.